Compare TCI & LAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TCI | LAB |
|---|---|---|
| Founded | 1983 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 350.0M | 347.5M |
| IPO Year | 1994 | 2008 |
| Metric | TCI | LAB |
|---|---|---|
| Price | $47.00 | $0.91 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.35 |
| AVG Volume (30 Days) | 2.9K | ★ 6.0M |
| Earning Date | 05-11-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 135.29 | 61.54 |
| EPS | 0.02 | ★ 0.33 |
| Revenue | $49,060,000.00 | ★ $101,937,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2.63 |
| P/E Ratio | $2,425.00 | ★ $2.63 |
| Revenue Growth | ★ 4.23 | N/A |
| 52 Week Low | $31.48 | $0.70 |
| 52 Week High | $59.65 | $1.72 |
| Indicator | TCI | LAB |
|---|---|---|
| Relative Strength Index (RSI) | 70.18 | 53.14 |
| Support Level | $43.23 | $0.90 |
| Resistance Level | $58.33 | $1.02 |
| Average True Range (ATR) | 2.37 | 0.07 |
| MACD | 0.95 | 0.01 |
| Stochastic Oscillator | 83.44 | 94.65 |
Transcontinental Realty Investors Inc is a fully integrated externally managed real estate company. It operates in two business segments: the acquisition, development, ownership and management of multifamily properties; and the acquisition, development, ownership and management of commercial properties; which are office properties. The services for its commercial segment include rental of office space and other tenant services, including parking and storage space rental. The services for its multifamily segment include rental of apartments and other tenant services, including parking and storage space rental. the company derives maximum revenue from Multifamily Segment.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.